This invention relates to a composition comprising 1.) a metal carboxylate, wherein the metal M is selected from the group consisting of Ag, Cn, Hg, Pb, Sn, Ni, Co, Ca, Fe, Zn and Mn, those metals being present as ions in a +2 or +3 charge state, and wherein the carboxylate anion is derived from a hydrocarbyl monocarboxylic acid having 5 to 20 carbon atoms, or a mixture of such acids, 2.) a solvent selected from the group consisting of water, glycol ethers having from 4 to 15 carbon atoms, alkyl alcohols having from 1 to 10 carbons, and aromatic hydrocarbon solvents having from 6 to 30 carbons, and 3.) an emulsion breaker which is a polymeric nonionic surfactant.

This invention relates to a composition comprising 1.) a metal carboxylate, wherein the metal M is selected from the group consisting of Ag, Cn, Hg, Pb, Sn, Ni, Co, Ca, Fe, Zn and Mn, those metals being present as ions in a +2 or +3 charge state, and wherein the carboxylate anion is derived from a hydrocarbyl monocarboxylic acid having 5 to 20 carbon atoms, or a mixture of such acids, 2.) a solvent selected from the group consisting of water, glycol ethers having from 4 to 15 carbon atoms, alkyl alcohols having from 1 to 10 carbons, and aromatic hydrocarbon solvents having from 6 to 30 carbons, and 3.) an emulsion breaker which is a polymeric nonionic surfactant.

A method of labelling biological molecules with .sup.18F, via attachment of fluorine to a metal complex, where the metal complex is conjugated to the biological molecule. The invention highlights the incorporation of hydrogen bonding (H-bonding) into the metal complex scaffold, and how this can be utilised to improve the kinetics of fluoride incorporation. Also provided are pharmaceutical compositions, kits and methods of in vivo imaging.

A method of labelling biological molecules with .sup.18F, via attachment of fluorine to a metal complex, where the metal complex is conjugated to the biological molecule. The invention highlights the incorporation of hydrogen bonding (H-bonding) into the metal complex scaffold, and how this can be utilised to improve the kinetics of fluoride incorporation. Also provided are pharmaceutical compositions, kits and methods of in vivo imaging.

Macrocyclic complexes and macrocyclic compounds. The macrocyclic complexes or macrocyclic compounds have a TACN moiety with one or more amine group(s) or a O- or S-substituted TACN moiety. The macrocyclic complexes have a high-spin Fe(III) atom coordinated to the TACN moiety. The macrocyclic complexes can be used in imaging methods.

The present invention relates to a peptide thiourea derivative, a pharmaceutically acceptable salt thereof, a radioisotope labeled compound comprising the same, and a pharmaceutical composition for treating or diagnosing prostate cancer comprising the same as an active ingredient. The peptide thiourea derivative of the present invention is excellent in stability in human serum when it is administered in vivo and not only binds well to PSMA expressed in prostate cancer but also inhibits excellently PSMA at a low concentration. Besides, the derivative of the invention has a high water-solubility and can be excreted through the kidney not through the bile passage so that a clear image of the tumor region of prostate cancer can be obtained. Therefore, the derivative of the present invention can be effectively used as a pharmaceutical composition for treating and diagnosing prostate cancer.

The present invention relates to a peptide thiourea derivative, a pharmaceutically acceptable salt thereof, a radioisotope labeled compound comprising the same, and a pharmaceutical composition for treating or diagnosing prostate cancer comprising the same as an active ingredient. The peptide thiourea derivative of the present invention is excellent in stability in human serum when it is administered in vivo and not only binds well to PSMA expressed in prostate cancer but also inhibits excellently PSMA at a low concentration. Besides, the derivative of the invention has a high water-solubility and can be excreted through the kidney not through the bile passage so that a clear image of the tumor region of prostate cancer can be obtained. Therefore, the derivative of the present invention can be effectively used as a pharmaceutical composition for treating and diagnosing prostate cancer.

Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.

Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.

The present disclosure generally relates to compositions and methods for ex vivo expansion of immune cells isolated from a subject, wherein gene expression can be modulated to enhance immune cell activity in the resulting expanded immune cell culture. Modulation of gene expression in an expanded immune cell culture allows for an immune cell therapy contains genetically chemically modified immune cells suitable for the adoptive cell transfer into a subject in need thereof.